Michael A. Zasloff (born July 2, 1946) is an American physician, medical researcher, and entrepreneur.
Michael Alan Zasloff was born to a Jewish family, the son a dentist and an artist.
[3] He did his residency training in pediatrics at the Boston Children's Hospital and a research fellowship at Johns Hopkins University.
[7] At Penn, working with Fred Kaplan, Zasloff continued research he had begun at the NIH on the cause and treatment of fibrodysplasia ossificans progressiva.
[8] He was with the company until its lead product, pexiganan, was rejected by the FDA in 1999 for lack of efficacy compared with the standard of care for diabetic foot ulcers, and he went to Georgetown University's medical school, where he was appointed Dean for Research and Translational Science.